P. Barditch‐Crovo

发表

Clinical Pharmacokinetics of 1-[((S)-2-Hydroxy-2-Oxo-1,4,2-Dioxaphosphorinan-5-yl)methyl]cytosine in Human Immunodeficiency Virus-Infected Patients

P. Lietman, B. Petty, K. Cundy, 1999, Antimicrobial Agents and Chemotherapy.

Anti-human immunodeficiency virus (HIV) activity, safety, and pharmacokinetics of adefovir dipivoxil (9-[2-(bis-pivaloyloxymethyl)-phosphonylmethoxyethyl]adenine) in HIV-infected patients.

C. Hendrix, J. Toole, H. Jaffe, 1997, The Journal of infectious diseases.

Pharmacokinetics, toxicity, and activity of intravenous dextran sulfate in human immunodeficiency virus infection

R. Chaisson, C. Flexner, H. Farzadegan, 1991, Antimicrobial Agents and Chemotherapy.

Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection

R. Siliciano, J. Margolick, R. Brookmeyer, 1997, Nature.

Phase I/II Trial of the Pharmacokinetics, Safety, and Antiretroviral Activity of Tenofovir Disoproxil Fumarate in Human Immunodeficiency Virus-Infected Adults

J. Kahn, P. Barditch-Crovo, A. Collier, 2001, Antimicrobial Agents and Chemotherapy.

Safety, Pharmacokinetics, and Antiretroviral Activity of Intravenous 9-[2-(R)-(Phosphonomethoxy)propyl]adenine, a Novel Anti-Human Immunodeficiency Virus (HIV) Therapy, in HIV-Infected Adults

Steven G. Deeks, James F. Rooney, J. Kahn, 1998, Antimicrobial Agents and Chemotherapy.

Prophylactic activity of atovaquone against Plasmodium falciparum in humans.

T. Shapiro, P. Barditch-Crovo, Nirbhay Kumar, 1999, The American journal of tropical medicine and hygiene.

Clinical pharmacokinetics of adefovir in human immunodeficiency virus type 1-infected patients

A. Collier, J. Toole, H. Jaffe, 1995, Antimicrobial agents and chemotherapy.

Relationship between plasma concentrations of 3'-deoxy-3'-fluorothymidine (alovudine) and antiretroviral activity in two concentration-controlled trials.

C Flexner, C. Flexner, M. Jacobson, 1994, The Journal of infectious diseases.

The effect of increasing gastric pH upon the bioavailability of orally-administered foscarnet.

R. Hafner, P. Lietman, J. Gambertoglio, 1998, Antiviral research.

Beneficial Pharmacokinetic Interaction Between Atazanavir and Lopinavir/Ritonavir

C. Flexner, K. Carson, E. Fuchs, 2007, Journal of acquired immune deficiency syndromes.

Lack of beta-oxidation defects in human immunodeficiency virus-positive subjects with and without chronic zidovudine exposure.

M. Wachsman, P. Lietman, C. Trapnell, 1996, Blood.

The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive

C. Flexner, E. Ette, P. Barditch-Crovo, 1999, Clinical pharmacology and therapeutics.

TruncationofKir 6 . 2 produces ATP-sensitiveK þ channels in theabsenceof the sulphonylurea receptor

R. Siliciano, J. Margolick, T. Chun, 1997 .

The role of protective HCP5 and HLA-C associated polymorphisms in the control of HIV-1 replication in a subset of elite suppressors

R. Siliciano, J. Blankson, J. Gallant, 2008, AIDS.

Quantitation of vaginally administered nonoxynol-9 in premenopausal women.

F. Witter, P. Stratton, F. Hamzeh, 1997, Contraception.

Intracranial leiomyosarcoma in a patient with AIDS

A. Olivi, P. Burger, R. R. Lee, 1999, Neuroradiology.

Duration of vaginal retention and potential duration of antiviral activity for five nonoxynol‐9 containing intravaginal contraceptives

F. Witter, L. Rocco, C. Trapnell, 1999, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

Determination of the spermicide nonoxynol-9 in vaginal lavage by high-performance liquid chromatography.

J. Nichols, F. Hamzeh, J. L. McPherson, 1996, Journal of chromatography. B, Biomedical applications.

Clonally expanded HIV-1 proviruses with 5′-leader defects can give rise to nonsuppressible residual viremia

R. Siliciano, J. Siliciano, C. Tremblay, 2023, The Journal of clinical investigation.

A Phase I/II Evaluation of Oral L‐2‐Oxothiazolidine‐4‐Carboxylic Acid in Asymptomatic Patients Infected with Human Immunodeficiency Virus

M. Lederman, D. Noe, P. Barditch-Crovo, 1998, Journal of clinical pharmacology.

Severe neutropenia among healthy volunteers given rifabutin in clinical trials

C. Flexner, P. Barditch-Crovo, P. Barditch‐Crovo, 2003 .

Clinic-Based Treatment of Opioid-Dependent HIV-Infected Patients Versus Referral to an Opioid Treatment Program

Richard D Moore, B. Lau, D. Fiellin, 2010, Annals of Internal Medicine.

Regional coronary endothelial dysfunction is related to the degree of local epicardial fat in people with HIV.

S. Lai, M. Schär, R. Weiss, 2018, Atherosclerosis.

Amprenavir and Lopinavir Pharmacokinetics following Coadministration of Amprenavir or Fosamprenavir with Lopinavir/Ritonavir, with or without Efavirenz

C. Flexner, P. Barditch-Crovo, K. Carson, 2007, Antiviral therapy.

A randomized, placebo-controlled, double-blinded clinical trial of colchicine to improve vascular health in people living with HIV

J. Margolick, S. Lai, M. Schär, 2021, AIDS.

Differential Effects of Tipranavir plus Ritonavir on Atorvastatin or Rosuvastatin Pharmacokinetics in Healthy Volunteers

C. Flexner, E. Fuchs, M. Elgadi, 2009, Antimicrobial Agents and Chemotherapy.

Adverse reactions to therapy for HIV infection.

R. Chaisson, P. Barditch‐Crovo, 1995, Emergency medicine clinics of North America.

Hydroxyurea does not enhance the anti-HIV activity of low-dose tenofovir disoproxil fumarate.

A. Collier, S. Deeks, I. McGowan, 2001, Journal of acquired immune deficiency syndromes.

Coronary artery endothelial dysfunction is present in HIV-positive individuals without significant coronary artery disease

Richard D Moore, S. Lai, M. Stuber, 2017, AIDS.

Clinic-based Treatment for Opioid-dependent HIV-infected Patients versus Referral to an Opioid Treatment Program : A Randomized Controlled Trial

Woodson, Richard D Moore, B. Lau, 2010 .

Coronary Endothelial Dysfunction in People Living With HIV Is Related to Body Fat Distribution

M. Schär, R. Weiss, P. Barditch-Crovo, 2022, Journal of acquired immune deficiency syndromes.